Specialist and experienced pricing and market access consultancy
We will develop and implement a successful launch strategy for your product.
We build payer focussed pricing and market access strategies to enable commercial success.
We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.
Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.
Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.
Individual solutions to suit you
We adapt our working style to reflect your needs
We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies
We react quickly and effectively to provide the best support possible
With the implementation of the EU HTA (Regulation (EU) 2025/117) and ongoing adaptation of methods u…
Read moreAs the regulatory and market access landscape continues to evolve across Europe, timely and strategi…
Read moreIn the current pharmaceutical environment, obtaining regulatory approval is no longer enough to ensu…
Read moreThe first joint clinical assessments under the new EU Health Technology Assessment (HTA) Regulation …
Read moreThe long-anticipated EU Health Technology Assessment (HTA) Regulation (Regulation (EU) 2021/2282) wa…
Read moreOn 21 March 2025, the European Commission hosted a public webinar to share updates on the implementa…
Read moreCelebrating its 25th anniversary, NICE hosted a conference looking back at its progress and ahead to…
Read moreThe advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p…
Read moreThere is no excerpt because this is a protected post.
Read more